Skip Navigation


Annals of Oncology Advance Access originally published online on March 9, 2007
Annals of Oncology 2007 18(5):917-924; doi:10.1093/annonc/mdm062
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/5/917    most recent
mdm062v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Culine, S
Right arrow Articles by Droz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Culine, S
Right arrow Articles by Droz, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

urogenital tumors

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)

S Culine1,*, P Kerbrat2, A Kramar1, C Théodore3, C Chevreau4, L Geoffrois5, NB Bui6, J Pény7, A Caty8, R Delva9, P Biron10, K Fizazi3, J Bouzy3 and JP Droz10

1 CRLC Val d'Aurelle, Montpellier
2 Centre Eugène Marquis, Rennes
3 Institut Gustave Roussy, Villejuif
4 Institut Claudius Régaud, Toulouse
5 Centre Alexis Vautrin, Nancy
6 Institut Bergonié, Bordeaux
7 Centre François Baclesse, Caen
8 Centre Oscar Lambret, Lille
9 Centre Eugène Papin, Angers
10 Centre Léon Bérard, Lyon, France

* Correspondence to: Dr S. Culine, Department of Medical Oncology, CRLC Val d'Aurelle, Parc Euromédecine, 34298 Montpellier Cedex 5, France. Tel: +33-467613152; Fax: +33-467613022; E-mail: stculine{at}valdorel.fnclcc.fr

Background: High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin.

Patients and methods: Patients received either three cycles of BE500P or four cycles of E500P every 3 weeks. Disease was defined according to the Institut Gustave Roussy prognostic model. Patients were retrospectively assigned into the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. A sample size of 250 patients was necessary for an expected favorable response rate (primary end point) of 90% and not more than a 10% difference between the two arms.

Results: Among 257 assessable patients, 124 and 122 patients achieved a favorable response in the 3BE500P and 4E500P arms, respectively (P = 0.34). Median follow-up was 53 months. The 4-year event-free survival rates were 91% and 86%, respectively (P = 0.135). The 4-year overall survival rates were not significantly different [five deaths versus 12 deaths, respectively (P = 0.096)]. Similar nonsignificant trends were observed in good IGCCCG prognosis patients.

Conclusions: Both regimens produced similar results in terms of favorable response rates. As the trial was underpowered for survival analyses, conclusive data would require a larger randomized trial. Unless such a study is done, 3BE500P is the treatment of choice for metastatic NSGCT patients.

Key words: chemotherapy, good-risk, testis cancer, germ cell cancer

Received for publication October 28, 2006. Revision received January 18, 2007. Accepted for publication January 23, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

in this issue

Ann Oncol 2007 18: 811. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 JCOHome page
X. Garcia-del-Muro, P. Maroto, J. Guma, J. Sastre, M. Lopez Brea, J. A. Arranz, N. Lainez, D. S. de Prado, J. Aparicio, J. M. Piulats, et al.
Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study
J. Clin. Oncol., November 20, 2008; 26(33): 5416 - 5421.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Bokemeyer
Bleomycin in Testicular Cancer: Will Pharmacogenomics Improve Treatment Regimens?
J. Clin. Oncol., April 10, 2008; 26(11): 1783 - 1785.
[Full Text] [PDF]

Home page
 JAMAHome page
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA, February 13, 2008; 299(6): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Stephenson, G. J. Bosl, R. J. Motzer, D. F. Bajorin, J. P. Stasi, and J. Sheinfeld
Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer
J. Clin. Oncol., December 10, 2007; 25(35): 5597 - 5602.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. de Wit
Refining the Optimal Chemotherapy Regimen in Good Prognosis Germ Cell Cancer: Interpretation of the Current Body of Knowledge
J. Clin. Oncol., October 1, 2007; 25(28): 4346 - 4349.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.